Skip to main content
Quest Diagnostics

COVID-19, flu, and RSV combination testing

Know more, sooner, with respiratory molecular combination testing

SARS-CoV-2 (COVID-19), influenza, RSV, and other respiratory viruses can present with similar symptoms such as fever, cough, and shortness of breath. For at-risk groups1-3 or patients with a more acute illness, an expedited diagnosis is crucial, so treatment can be initiated while it’s most effective.1-3 That’s why it’s important to test for each of these illnesses at the same time.

Testing that supports a faster diagnosis

When a patient presents in-office with respiratory illness symptoms, send the specimen directly to Quest for the convenience of combination testing. Our SARS-CoV-2 (COVID-19) and respiratory molecular combination tests use a single specimen to test for common respiratory viruses, providing timely results to help you develop an appropriate care plan.

Why choose SARS-CoV-2 (COVID-19) and respiratory molecular combination tests for your patients

Distinguishes between SARS-CoV-2 (COVID-19), influenza A and B, RSV, and other respiratory pathogens with just 1 swab

Eliminates the need for multiple tests or patient visits—helping to speed up the time to a diagnosis

Reduces diagnostic uncertainty and can help guide early treatment management decisions4

Highly sensitive and specific, nucleic acid amplification tests (also known as molecular tests) capable of detecting 1 or more viruses are the diagnostic “gold standard”4

Combination testing options from Quest Diagnostics

Other respiratory testing options

Panel components may be ordered separately.

PSC testing availability

SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT combination test is available for collection at Quest Patient Service Centers (PSCs) for patients with mild symptoms.
Find a Quest PSC near you
39992-50-50.jpg

COVID-19 testing statements

  • The Quest Diagnostics molecular test, the other authorized molecular tests (together the “molecular tests”), the COVID/Flu molecular test, the COVID/Flu/RSV test, and the antibody test (together “the tests”) have not been FDA cleared or approved;
  • The tests have been authorized by FDA under an EUA for use by authorized laboratories;
  • The molecular tests have been authorized only for the unsupervised self-collection and maintenance of nasal specimens for the detection of nucleic acid from SARS CoV-2, not for any other viruses or pathogens;
  • The COVID/Flu molecular test and self-collection kit have been authorized only for the unsupervised self-collection and maintenance of nasal specimens for as an aid in detection of nucleic acid from SARS-CoV-2 and influenza A virus and influenza B virus, not for any other viruses or pathogens;
  • The COVID/Flu/RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
  • The antibody test has been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens; and,
  • The tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.


References

  1. 1CDC. Testing for COVID-19. Updated June 25, 2024. Accessed August 23, 2024. https://www.cdc.gov/covid/testing/index.html
  2. CDC. Weekly US Influenza Surveillance Report. Updated August 16, 2024. Accessed August 23, 2024. https://www.cdc.gov/flu/weekly/index.htm
  3. CDC. Clinical Overview of RSV. Updated July 3, 2024. Accessed August 23, 2024. https://www.cdc.gov/rsv/hcp/clinical-overview/index.html
  4. Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s diagnostics committee. Clin Infect Dis. 2020;71(10):2744-2751. doi:10.1093/cid/ciaa508

Questions?

For more information on our combination testing solutions, or to set up a Quest account, connect with a Quest representative.

Contact us

COVID-19

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.